e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Edgewise Therapeutics, Inc. - Common Stock
(NQ:
EWTX
)
23.71
+0.39 (+1.67%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 4, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Edgewise Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
52 Biggest Movers From Friday
↗
January 31, 2022
Gainers Knightscope, Inc. (NASDAQ: KSCP) surged 175.6% to close at $3.40 on Friday. The company, on Thursday, priced its IPO at $10 per share. Imperial Petroleum Inc. (NASDAQ:...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
January 28, 2022
Gainers Provention Bio (NASDAQ:PRVB) stoc...
Via
Benzinga
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
↗
August 18, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
↗
August 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc...
Via
Benzinga
Stocks Move Higher Midday, Still Pacing for Weekly Losses
↗
January 28, 2022
Stocks are continuing their rollercoaster pattern midday, as Wall Street attempts to lift itself out of the worst selloff since March 2020.
Via
Talk Markets
33 Stocks Moving In Friday's Mid-Day Session
↗
January 28, 2022
Gainers Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 126% to $2.6219. Imperial Petroleum, last month, posted Q3 revenue of $4.1 million. Yoshitsu Co., Ltd (NASDAQ: TKLF...
Via
Benzinga
50 Biggest Movers From Yesterday
↗
January 06, 2022
Gainers Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares surged 63.7% to settle at $2.21 on Wednesday after the company announced that in preclinical studies its lead...
Via
Benzinga
Mid-Afternoon Market Update: Nasdaq Down 300 Points; Annexon Shares Plunge
↗
January 05, 2022
Toward the end of trading Wednesday, the Dow traded up 0.24% to 36,711.36 while the NASDAQ fell 1.93% to 15,321.38. The S&P also fell, dropping 0.80% to 4,755.18. The U.S. has...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
January 05, 2022
Gainers Lixte Biotech Holdings (NASDAQ:LIXT) stock increased by 70.4% to $2.3 during Wednesday's regular session. Trading volume for this security as of 12:31 EST is...
Via
Benzinga
34 Stocks Moving In Wednesday's Mid-Day Session
↗
January 05, 2022
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 49.7% to $15.45 after the company announced it acquired exclusive rights to novel mRNA biomarkers. Data Storage...
Via
Benzinga
Edgewise Therapeutics Shares Jump After Positive Data On Becker Muscular Dystrophy Study
↗
January 05, 2022
Edgewise Therapeutics Inc (NASDAQ: EWTX) posted positive topline results from Phase 1b trial of EDG-5506, designed to protect injury-susceptible fast skeletal...
Via
Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets
↗
January 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon,...
Via
Benzinga
Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD)
January 05, 2022
From
Edgewise Therapeutics
Via
Business Wire
The Week Ahead In Biotech (Jan. 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week
↗
January 02, 2022
Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. Here are the key catalysts that can sway biotech stocks in the unfolding week.
Via
Talk Markets
The Week Ahead In Biotech (Jan 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week
↗
January 02, 2022
Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. On the regulatory front, the Food And Drug Administration...
Via
Benzinga
63 Biggest Movers From Friday
↗
December 20, 2021
Gainers Spruce Biosciences, Inc. (NASDAQ: SPRB) jumped 102.8% to close at $5.03 on Friday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $15...
Via
Benzinga
Edgewise Therapeutics to Report Phase 1b Topline Results of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) on January 5, 2022, and Initiates ARCH Follow-On Open Label BMD Study
December 15, 2021
From
Edgewise Therapeutics
Via
Business Wire
60 Biggest Movers From Yesterday
↗
December 07, 2021
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 200.4% to close at $15.05 on Monday after the company announced the commencement of a formal process to explore...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
December 06, 2021
Gainers Adicet Bio (NASDAQ:ACET) shares i...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
December 03, 2021
Gainers Celyad Oncology (NASDAQ:CYAD) stock moved upwards by 32.58% to $4.72 during Friday's regular session. Trading volume for this security as of 12:30 EST is 45.2...
Via
Benzinga
Edgewise Therapeutics to Participate at Evercore ISI 4th Annual HEALTHCONx Conference on December 2
November 17, 2021
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Reports Third Quarter 2021 Financial Results
November 10, 2021
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Posts Data From Early-Stage Muscle Wasting Disease Trial
↗
October 28, 2021
Edgewise Therapeutics Inc (NASDAQ: EWTX) has announced topline results from the MAD portion of Phase 1 trial of EDG-5506, designed to protect skeletal muscle...
Via
Benzinga
Edgewise Therapeutics Announces Positive Topline Results from the EDG-5506 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HVs) and Doses First Becker Muscular Dystrophy (BMD) Patients
October 28, 2021
From
Edgewise Therapeutics
Via
Business Wire
Chief Scientific Officer Of Edgewise Therapeutics Sold $1.07 Million In Stock
↗
September 28, 2021
Russell Alan J, Chief Scientific Officer at Edgewise Therapeutics (NASDAQ:EWTX), made a large insider sell on September 27, according to a new SEC filing. What Happened: A Form 4...
Via
Benzinga
Topics
Regulatory Compliance
Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event on September 23
September 14, 2021
From
Edgewise Therapeutics
Via
Business Wire
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
↗
August 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...
Via
Benzinga
Topics
Intellectual Property
Edgewise's Inherited Neuromuscular Disorder Candidate Receives FDA Fast Track Tag
↗
August 16, 2021
The FDA has granted Fast Track designation to Edgewise Therapeutics Inc's (NASDAQ: EWTX) EDG-5506 for Becker Muscular Dystrophy (BMD). EDG-5506, a...
Via
Benzinga
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Individuals with Becker Muscular Dystrophy (BMD)
August 16, 2021
From
Edgewise Therapeutics
Via
Business Wire
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
↗
August 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.